ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)
Trial details
- Registry ID
- NCT05081245
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)NCT05081245 | MapLight Therapeutics | Phase 2 | Completed | 2026-03-10Actual |
| ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)NCT05889273 | MapLight Therapeutics | Phase 2 | Active not recruiting | 2027-11Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |